Oculis has developed a drug delivery platform consisting of a novel technique to facilitate drug absorption to both anterior and posterior parts of the eye. The advantage is a drug delivery system where diseases of the posterior part of the eye can be treated with a simple topical application, i.e. an eye drop.
DexNP would be the first eye drops to treat DME and intermediate/posterior uveitis. Available drugs for DME are invasive, either intravitreal injections or implants and current treatments for uveitis involve intravitreal injections or oral corticosteroids.